Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 15 | 2025 | 294 | 3.070 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2025 | 225 | 1.870 |
Why?
|
| Aortic Valve Stenosis | 5 | 2025 | 353 | 1.780 |
Why?
|
| Acute Coronary Syndrome | 7 | 2025 | 247 | 1.730 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2024 | 118 | 1.600 |
Why?
|
| Coronary Stenosis | 2 | 2024 | 77 | 1.470 |
Why?
|
| Coronary Angiography | 7 | 2024 | 451 | 1.180 |
Why?
|
| Coronary Artery Bypass | 10 | 2023 | 516 | 1.000 |
Why?
|
| Myocardial Infarction | 7 | 2025 | 998 | 0.940 |
Why?
|
| Aortic Valve | 5 | 2025 | 456 | 0.940 |
Why?
|
| Coronary Artery Disease | 9 | 2025 | 891 | 0.860 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 646 | 0.850 |
Why?
|
| Nitroglycerin | 1 | 2024 | 22 | 0.850 |
Why?
|
| Coronary Vasospasm | 1 | 2024 | 12 | 0.840 |
Why?
|
| Lithotripsy | 2 | 2021 | 22 | 0.820 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2021 | 20 | 0.800 |
Why?
|
| Vasodilator Agents | 1 | 2024 | 198 | 0.760 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 22 | 0.740 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 202 | 0.730 |
Why?
|
| Treatment Outcome | 24 | 2025 | 12874 | 0.570 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 420 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.510 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 2111 | 0.510 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 167 | 0.510 |
Why?
|
| Stroke | 3 | 2022 | 1055 | 0.500 |
Why?
|
| American Heart Association | 1 | 2018 | 325 | 0.470 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2022 | 428 | 0.470 |
Why?
|
| Heart Diseases | 1 | 2020 | 501 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 363 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.450 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 851 | 0.440 |
Why?
|
| Atherosclerosis | 4 | 2023 | 950 | 0.440 |
Why?
|
| Humans | 53 | 2025 | 130483 | 0.430 |
Why?
|
| Electrocardiography | 4 | 2024 | 974 | 0.420 |
Why?
|
| Stents | 3 | 2025 | 781 | 0.400 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 786 | 0.380 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2024 | 275 | 0.360 |
Why?
|
| Angina Pectoris | 2 | 2024 | 56 | 0.360 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2025 | 219 | 0.330 |
Why?
|
| Postoperative Complications | 5 | 2019 | 3118 | 0.310 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2022 | 180 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 751 | 0.300 |
Why?
|
| Aged | 15 | 2025 | 20901 | 0.290 |
Why?
|
| Middle Aged | 14 | 2025 | 28400 | 0.250 |
Why?
|
| Diagnosis, Differential | 3 | 2024 | 1889 | 0.230 |
Why?
|
| Ultrasonography, Interventional | 2 | 2025 | 212 | 0.230 |
Why?
|
| Risk Factors | 11 | 2025 | 10950 | 0.220 |
Why?
|
| Comorbidity | 4 | 2022 | 1587 | 0.200 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 45 | 0.200 |
Why?
|
| Hospital Mortality | 4 | 2022 | 1065 | 0.200 |
Why?
|
| Vascular Calcification | 2 | 2020 | 70 | 0.190 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 172 | 0.190 |
Why?
|
| Cocaine-Related Disorders | 1 | 2024 | 205 | 0.180 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 100 | 0.180 |
Why?
|
| Ventricular Function, Left | 1 | 2025 | 543 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 1267 | 0.170 |
Why?
|
| Endocarditis | 1 | 2022 | 103 | 0.170 |
Why?
|
| Hypothermia | 1 | 2021 | 61 | 0.170 |
Why?
|
| Male | 17 | 2025 | 64563 | 0.170 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 47 | 0.170 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2021 | 20 | 0.170 |
Why?
|
| Catheterization, Peripheral | 1 | 2022 | 126 | 0.170 |
Why?
|
| Inpatients | 2 | 2022 | 550 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2025 | 3686 | 0.160 |
Why?
|
| Atherectomy, Coronary | 1 | 2020 | 7 | 0.160 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 81 | 0.160 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 171 | 0.160 |
Why?
|
| Carotid Arteries | 1 | 2021 | 125 | 0.160 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 161 | 0.160 |
Why?
|
| Preoperative Care | 2 | 2012 | 358 | 0.160 |
Why?
|
| Hospital Costs | 1 | 2021 | 182 | 0.160 |
Why?
|
| Heart Atria | 1 | 2022 | 333 | 0.150 |
Why?
|
| Aspirin | 1 | 2021 | 215 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3033 | 0.150 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 184 | 0.150 |
Why?
|
| Smoking | 1 | 2024 | 923 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 439 | 0.140 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 321 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2298 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 320 | 0.130 |
Why?
|
| Female | 16 | 2025 | 70322 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 358 | 0.130 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 62 | 0.130 |
Why?
|
| Cocaine | 1 | 2018 | 209 | 0.120 |
Why?
|
| Age Factors | 2 | 2020 | 2835 | 0.120 |
Why?
|
| Pandemics | 2 | 2021 | 1153 | 0.120 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 5 | 0.120 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 15 | 0.120 |
Why?
|
| Mitral Valve | 3 | 2022 | 246 | 0.120 |
Why?
|
| United States | 7 | 2023 | 11828 | 0.110 |
Why?
|
| Heart Failure | 2 | 2025 | 2320 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 734 | 0.100 |
Why?
|
| Time Factors | 4 | 2025 | 6203 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 244 | 0.100 |
Why?
|
| Behavior Therapy | 1 | 2015 | 271 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 157 | 0.090 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 100 | 0.090 |
Why?
|
| Aging | 1 | 2020 | 1253 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1445 | 0.090 |
Why?
|
| Colchicine | 1 | 2012 | 39 | 0.090 |
Why?
|
| Pericarditis | 1 | 2012 | 43 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 1792 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2025 | 701 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 379 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 217 | 0.080 |
Why?
|
| Cause of Death | 1 | 2013 | 503 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 265 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2024 | 492 | 0.080 |
Why?
|
| Pneumonia | 1 | 2012 | 338 | 0.070 |
Why?
|
| Prognosis | 1 | 2018 | 4895 | 0.070 |
Why?
|
| Sepsis | 1 | 2012 | 496 | 0.070 |
Why?
|
| Registries | 1 | 2015 | 1605 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2021 | 429 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2012 | 5072 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2025 | 537 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2024 | 731 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1925 | 0.050 |
Why?
|
| Radial Artery | 1 | 2022 | 33 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2013 | 17622 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 51 | 0.050 |
Why?
|
| Incidence | 2 | 2025 | 3330 | 0.050 |
Why?
|
| Mediastinum | 1 | 2022 | 45 | 0.040 |
Why?
|
| Hematoma | 1 | 2022 | 88 | 0.040 |
Why?
|
| Coma | 1 | 2021 | 56 | 0.040 |
Why?
|
| Adult | 4 | 2023 | 31138 | 0.040 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2021 | 25 | 0.040 |
Why?
|
| Survival Rate | 2 | 2019 | 2130 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2021 | 88 | 0.040 |
Why?
|
| Atherectomy | 1 | 2020 | 11 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 101 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 258 | 0.040 |
Why?
|
| Health Resources | 1 | 2021 | 126 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 5186 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 193 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2023 | 275 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 346 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 540 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 259 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 9 | 0.040 |
Why?
|
| Propanolamines | 1 | 2018 | 18 | 0.040 |
Why?
|
| Atenolol | 1 | 2018 | 44 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 21 | 0.030 |
Why?
|
| Propranolol | 1 | 2018 | 111 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2022 | 1108 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1164 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1399 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 623 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 832 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 509 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 693 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 680 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1395 | 0.030 |
Why?
|
| Global Health | 1 | 2019 | 626 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3388 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3802 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2015 | 6428 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 808 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 6783 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 330 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 1160 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1334 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 1215 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1803 | 0.020 |
Why?
|
| Texas | 1 | 2012 | 3626 | 0.010 |
Why?
|